SWITZERLAND –Commercial-stage biotechnology company ADC Therapeutics has elected industry veteran Mohamed Zaki, MD, Ph.D., as its new Chief Medical Officer (CMO), effective January 3, 2023.
He succeeds Sridhar Venkatesh, Dr. Joseph Camardo, MD, who is stepping down from full-time work to pursue alternative avenues to engage with the pharmaceutical industry and patient community.
In a press release, ADC Therapeutics announced that Dr. Mohamed Zaki will serve on the Company’s executive leadership team.
The Lausanne-based company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody-drug conjugates (ADCs) outlined that he has spent over 20 years in oncology and hematology drug development.
With a vast wealth of industry knowledge and proven insight, he is well-suited to continue steering ADC Therapeutics in the evolving field of antibody-drug conjugates.
Dr. Zaki has served as Vice President & Global Head of Oncology Development at AbbVie. Prior to his tenure at AbbVie, he spent 9 years at Celgene.
He also worked at Sanofi-Aventis and Centocor, Inc., a subsidiary of Johnson & Johnson.
Furthermore, Mohamed Zaki came to the United States after finishing medical school in Egypt, where he gained a Ph.D. at the University of Pennsylvania, before becoming an assistant professor.
He served on the faculty of the University of Pennsylvania and Ain Shams University School of Medicine in Cairo, Egypt.
On his appointment, Dr. Zaki said: “I look forward to working with the Company’s experienced team of researchers to expand on their innovative science and bring more therapeutic options to those impacted by cancer worldwide.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics, lauded Dr. Camardo for his tireless commitment to ADC Therapeutics and people living with cancer around the world as he welcomed the recently appointed Chief Medical Officer.
He said that the Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
“We are excited to welcome Dr. Zaki to ADC Therapeutics and look forward to his leadership in developing our deep pipeline of antibody-drug conjugates,” Mallik concluded.